Sector News

Amgen Appoints Jonathan P. Graham Senior Vice President, General Counsel And Secretary

May 20, 2015
Life sciences
/PRNewswire/ – Amgen today announced the appointment of Jonathan P. Graham as senior vice president, general counsel and secretary, effective July 13, 2015. He will be responsible for Amgen’s legal operations, reporting to Robert A. Bradway, chairman and chief executive officer. Graham will succeed David J. Scott who is retiring Aug. 31, 2015.
 
Graham, 55, joins Amgen from Danaher Corporation, where he has served as senior vice president and general counsel, responsible for all legal, governance, regulatory, risk, and compliance matters.
 
Previously, Graham was vice president, litigation and legal policy at General Electric Company and a partner at Williams & Connolly LLP. He also served as a law clerk to the Honorable Joseph T. Sneed, U.S. Court of Appeals for the Ninth Circuit. Graham received his bachelor’s degree from Pitzer College and his J.D. from the University of Texas School of Law, where he was editor-in-chief of the Texas Law Review. 
 
Bradway said, “We are excited to have Jon join our team.  His proven leadership skills and depth of experience will serve us well as we drive our agenda for growth.”
 
Source: Amgen

comments closed

Related News

June 16, 2024

Bayer’s biotech head Jens Vogel says good-bye after 4 years

Life sciences

While Vogel didn’t cite any broader organizational changes as the reason behind his resignation, his departure comes amid a heavy-handed restructuring at the German pharma. Back in January, Bayer unveiled plans that have ultimately led to the elimination of more than 1,500 roles in the first three months of 2024.

June 16, 2024

Ventilator maker Vyaire Medical files for bankruptcy

Life sciences

The global ventilation and respiratory device manufacturer—originally spun out as a joint venture between BD and Apax Partners in 2016—said its decision followed “below-plan performance in the first half of the financial year, which frustrated efforts to refinance company debt,” and that Vyaire will remain open for business in the interim.

June 16, 2024

Pfizer, Flagship name first target for multibillion-dollar collaboration: obesity

Life sciences

Pfizer and Flagship Pioneering have settled on the first target for their billion-dollar, multiprogram collaboration, and it’s not exactly a surprise: The New York Big Pharma giant will work with the venture creation firm’s ProFound Therapeutics to develop new obesity drugs.

How can we help you?

We're easy to reach